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http://dxObjectives: We developed a multimodal optical imaging system for intraoperative visualization of sentinel
lymph nodes (SLNs). This study is to validate our system by showing SLNs in the lung through combined optical
color and fluorescent image with indocyanine green (ICG) and ICG with human serum albumin (HSA).
Methods: Identical ICG concentrations of ICG only or ICG:HSAwas injected into the rat footpad and porcine
lung. Absolute amounts of the fluorescents were scaled on the basis of animal weights. The entire procedures
were recorded using color and near-infrared (NIR) charge-coupled device (CCD) cameras simultaneously,
and the 2 images were merged by real-time image processing software. All fluorescence intensity signals to
background ratio (SBR) and retention rates at SLN for both fluorescents were estimated and compared.
Results: This newly developed intraoperative color and fluorescence optical imaging system successfully visu-
alized the SLNs in animal experiments. The SLNs were identified 100% for both rat and pig under in vivo con-
ditions. Real-time image processing software overcame the low signal of NIR fluorescence images. ICG and
ICG:HSA provided no significantly different SBR in the SLN images for both rat thigh and pig lung.
Conclusions: The intraoperative optical imaging system enabled real-time image-guided surgery during SLN
mapping in lung in an animal model. The ICG retention rate was similar to ICG:HSA. ICG alone can be useful
for SLN imaging during lung cancer surgery. (J Thorac Cardiovasc Surg 2013;146:1509-15)The technique of sentinel lymph node (SLN) biopsy is
a minimally invasive method of identifying the patients at
greater risk and facilitating the selective use of more aggres-
sive surgical and systemic therapies to improve outcomes
with little additional morbidity.1 It is currently regarded as
the standard treatment method for malignant melanoma
and breast cancer, and applications are expanding to other
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SIn 1999, Little and colleagues2 first demonstrated that
the detection rate of SLN in vivo is less than 50% for
patients with lung cancer when isosulfan blue dye is
used owing to poor visibility, particularly in the presence
of intrathoracic black-pigmented anthracotic lymph
nodes.3,4 Since Liptay and colleagues5 reported radiotracer
methods using technetium 99m sulfur colloid with an 82%
identification rate and a 95% accuracy rate, radioisotopes
have been used in most studies of SLN mapping in lung
cancer. However, when the primary lesion is directly in-
jected with radioactive tracer, its radioactivity is so strong
that the radioactivity of the true SLNs is masked,6 espe-
cially SLNs that are located at the hilar area in lung cancer.
This phenomenon (called shine-through phenomenon)
makes in vivo identification of SLNs more difficult in
lung cancer with its complex and aberrant patterns of lym-
phatic drainage.4 To overcome this drawback, the surgeons
should be trained to measure carefully the radioactivity of
each lymph node and endure a certain period of learning
curve. For this reason, the Cancer and Leukemia Group
B (CALGB) 140203 multi-institutional phase 2 trial inves-
tigating the intraoperative SLN mapping in lung cancer
using radioisotope was unsuccessful,7 although many
single-center trials including our studies showed successful
results.8-12
Recently, the near-infrared (NIR) fluorescence imaging
system has attracted considerable interest in the field of
SLN identification.13 Optical imaging using the NIRdiovascular Surgery c Volume 146, Number 6 1509
Abbreviations and Acronyms
CCD ¼ charge-coupled device
HSA ¼ human serum albumin
ICFIS ¼ intraoperative color and fluorescence
imaging system
ICG ¼ indocyanine green
NIR ¼ near-infrared
SBR ¼ signal to background ratio
SLN ¼ sentinel lymph node




Sfluorescent lymphatic tracer enables real-time visualization
of lymphatic channels and SLNs during operation.14 There-
fore, NIR fluorescence imaging could provide an alternative
for, or an addition to, conventional techniques used for SLN
mapping with several advantages such as better penetration
and visibility than blue dyes and capability of real-time
visualization and removing ionizing radiation over
radiotracers.6,15
Indocyanine green (ICG) is the only clinically available
NIR fluorescent lymphatic tracer.16 Even if the dye itself
is not visible in anthracotic lymph nodes,17 its fluores-
cence is in the NIR region and can be easily detected
with an infrared camera. However, it is said that ICG
has some problems as an optimal tracer: relatively low
fluorescence brightness and small hydrodynamic diame-
ter, which can lead it to flow to higher-tier lymph nodes
with poor retention in the SLN.14 Ohnishi and col-
leagues18 have demonstrated that adsorption of ICG to
human serum albumin (HSA), by simply premixing ICG
with HSA, can increase the fluorescence intensity and
the hydrodynamic diameter, giving it better SLN retention
with an improved detection rate over ICG alone in the
preclinical trials.
We developed an optical imaging system, called intrao-
perative color and fluorescence imaging system (ICFIS),
that provides color and fluorescence images of the target tis-
sues along with their fused images. It allows the surgeon to
identify SLNs intraoperatively within the context of surgi-
cal anatomy. In this study, before clinical application of
the ICFIS in SLN mapping in lung cancer, we evaluated
the clinical usefulness of 2 fluorescents including ICG
and ICG:HSA in animal models.MATERIALS AND METHODS
Intraoperative Color and Fluorescence Imaging
System
The ICFIS sits on a custom-manufactured 105 H 3 60 D 3 120 H cm
moving cart with 4 rotating and locking wheels. An articulating arm boom
stand with 780-mm maximum extension and 210 mm articulating range
firmly holds the system (Figure 1, A).
An excitation beam from a 750-nm diode laser up to 1.2 W (SDL-750-
LM-XXXT; Shanghai DLT Co, Ltd, Shanghai, China) is delivered to the
region of interest via a 2-m long flexible bifurcated light guide. Beam1510 The Journal of Thoracic and Cardiovascular Surintensities were measured at 10 mW/cm2 for rat and 5 mW/cm2 for pig,
each of which was optimized on the basis of the injected volume of the
fluorophore.
Both reflected white light and fluorescence are collected with a zoom
lens. The working distance between the zoom lens and object is set to 60
cm. The surgical field of view is set to 40 W 3 30 H cm (Figure 1, B).
The white light and fluorescence are separated by a dichroic mirror with
a cutoff frequency of 675 nm. The fluorescence reflected off the dichroic
mirror passes through a 1-inch long wavelength pass filter at 808 nm before
reaching a NIR charge-coupled device (CCD) camera (CM-141MCL; JAI
Ltd, Yokohama, Japan). Reflected light that is transmitted through the
dichroic mirror is further filtered via another 1-inch short-wavelength
pass filter at 650 nm and detected by a color CCD camera (IMC-15FT;
IMI-tech, Anyang, Korea) (Figure 1, C).
Each camera produces images at different frames per second (30 for
NIR CCD camera and 15 for color CCD camera). Only the NIR images
were processed using software so that only the signal over a certain thresh-
old is captured, which is later overlaid on top of the color image during real-
time visualization.
Preparation of ICG and ICG:HSA
ICG (25-mg vials) was purchased from Jeil Pham (Daiichi-Sankyo
Korea Co, Ltd; Seoul, Korea) and was dissolved in 10 mL of saline solution
to yield a 2.5-mg/mL (3.2-mmol/L) stock solution. ICG, 10, 20, 40, and 80
mL, was mixed with 1.25, 2.5, 5, 10 mL, respectively, of 20%HSA solution
(SK Chemical, Seoul, Korea) to yield ICG in HSA (ICG:HSA) at various
concentrations (3.2, 6.4, 12.8, and 32 mmol/L).
Animal Preparation
Five-week-old female rats (SK Chemical, Seoul, Korea) of 200 g were
used for in vivo experiments. They were administered 20 mg/kg of zolaze-
pam plus tiletamine (Zoletil; Vairbac, Carros, France) intramuscularly, and
either ICG or ICG:HSA was injected into the footpad. Each group com-
prised 5 animals. At each different time after injection, the ipsilateral leg
was exposed from foot to inguinal area by skin incision. Lymphatic flow
of this area was observed in real time using ICFIS, and the first lymph
node was identified and removed.
Female Yorkshire pigs (Yokenongzang; Yeonchen, Korea) weighing
a mean of 30 kg had anesthesia induced with 10-mg/kg intramuscular
xylazine (Rompun; Bayerkorea, Seoul, Korea). A mechanical ventilator
was connected to the tracheostomy site and anesthesia was maintained
with 2% isoflurane (Baxter Healthcare, Deerfield, Ill). The vital signs
were monitored throughout the operation by a clinical anesthetist. Unilat-
eral chest wall resection was performed from the second intercostal space
to the diaphragm level to obtain the whole image of the thoracic cavity in-
cluding lung andmediastinal structures (Figure 2). Resection could be done
with conventional devices such as a rib cutter and electrocauterization. Pul-
monary lymphatic mapping was performed by injecting ICG or ICG:HSA
intraparenchymally using a tuberculin syringe. Each group comprised 2
animals. Injections were positioned approximately 1-cm deep into the lat-
eral surface of the left upper lobes. Lymphatic flow was visualized in real
time using ICFIS. The first lymph node encountered on the path delineated
by the fluorescent lymphatics was defined as the SLN. All procedures were
approved by the Korea University Medical Center’s Animal Experimenta-
tion Committee and were carried out in accordance with the institutional
guidelines for the care and use of laboratory animals.
Statistical Analysis
For comparing the signal to background ratio (SBR) of in vivo SLN in
rat between ICG and ICG:HSA, Wilcoxon rank-sum test was performed.
Null hypotheses of no difference were rejected if P values were less than
.05. Statistical software (SPSS for Windows, version 12.0; SPSS, Inc,
Chicago, Ill) was used for statistical analysis.gery c December 2013
FIGURE 1. Intraoperative color and fluorescence imaging system. A, System mounted on a moving cart. B, Magnified image of the optics and camera
arrays. The working distance between the zoom lens and object was set to 60 cm and the field of view was set to 40 cm W 3 30 cm H to cover the entire
parts of the lung. C, Details of parts shown in B. Illustration of light paths of color and fluorescence light. NIR, Near-infrared; CCD, charge-coupled device.
Oh et al Evolving Technology/Basic ScienceRESULTS
Intraoperative Color and Fluorescence Imaging
System
ICFIS successfully visualized the NIR fluorescence from
all SLNs during the entire surgical procedure under the or-
dinary bright surgical environment. Inasmuch as NIR light
is invisible to the human eye, the surgical view was not dis-
turbed by NIR excitation light nor by the NIR fluorescence
of SLN tracers. Inasmuch as the long wavelength portion of
the bright room light slightly contaminates the fluorescence
image, the contrast of the NIR fluorescence images was
manually controlled using software depending on the surgi-
cal field conditions. Modulated NIR fluorescence images
were then pseudocolored, overlaid on the color images,
and finally displayed on the monitors in real time.FIGURE 2. Schema of Yorkshire pig with surgical field image. Unilateral
chest wall resection was performed to obtain the whole image of the tho-
racic cavity including lung and mediastinal structures.
The Journal of Thoracic and Car
SDose Optimization of ICG and ICG:HSA In Vivo
ICG and ICG:HSA exhibits intense quenching (ie, reduc-
tion of fluorescence emission) as its concentration is
increased over a certain threshold.14 To determine the opti-
mal concentration of ICG and ICG:HSA, we first measured
the fluorescence intensities of ICG and ICG:HSA at various
concentrations. The optimal dose of ICG or ICG:HSA
in vivo was supposed to be different from the dose in vitro
when the 2 fluorescents mixed with lymph fluid of body.18
Therefore, we tested the concentration-dependent fluores-
cent intensity in in vivo conditions. ICG and ICG:HSA at
concentrations of 3.2, 6.4, 12.8, and 32 mmol/L were
injected into the rat footpad (Figure 3, A). The stained lym-
phatic vessels and nodes were observed at 30 minutes after
injection using the ICFIS. We found that both ICG and
ICG:HSA at 12.8 mmol/L provided the highest SBR in
lymph nodes (Figure 3, B). Considering the average weight
of rats, the dosage of ICG is calculated as 5 mg/kg.E
T
/BComparison Between ICG Versus ICG:HSA
In vivo and ex vivo NIR fluorescence images of lymph
nodewere obtained at 5, 30, 60, and 120minutes after injec-
tion with 5 mg/kg of ICG or ICG:HSA (12.8 mmol/L in 0.1
mL). The SLNs were identified in 10 (100%) 10 rats under
in vivo conditions (Figure 4, A). SBRs of the ICG and
ICG:HSA mapped in lymph nodes were not significantly
different in the 2 groups (P ¼ .28, .89, .15, and .19 at times
of 5, 30, 60, and 120 minutes) (Figure 4, B), which showed
similar fluorescence intensities in both groups.
To validate whether this system has a potential clinical
use, we carried out preclinical studies with large animals.diovascular Surgery c Volume 146, Number 6 1511
FIGURE 3. Optimization of ICG and ICG:HSA dose as a function of the complex trade-off between fluorescence quenching at the dilution of fluorophore
in lymphatic channels. A, Right thigh (square) images of each rat were captured. B, Optimization of ICG and ICG:HSA mapped lymph node. A different
dose of ICG and ICG:HSA (3.2 to 32 mol/L) was injected into the rat food pad. Each is displayed in NIR fluorescence images (left columns) and fusion
images (right columns) using excitation light at 10 mW/cm2. ICG, Indocyanine green; HSA, human serum albumin; NIR, near-infrared.




SAfter opening the porcine chest, we injected 5 mg/kg of both
fluorescents (128 mmol/L in 1.5 mL) at the lateral surface of
the left upper lobe lung parenchyma in all pigs, a concentra-
tion consistent with the study in rats. In ICG cases, the SLNs
were successfully visualized at the para-aortic area using
ICFIS at around 7 minutes after injection. However,
ICG:HSA was detected around 2 minutes later than ICG,
consistent with other studies.19 All the SLNs were identified
in 4 (100%) pigs under in vivo conditions. ICG provided
slightly higher total fluorescence yield in SLN than
ICG:HSA (15.1 vs 7.2) (Figure 5). However, the SLN visi-
bilities for both fluorescents were not significantly different.
DISCUSSION
Inasmuch as the world’s population is aging, many
thoracic surgeons are now faced with a growing number
of patients with resectable lung cancer who have cardiopul-
monary dysfunction or extensive comorbidities.11 The SLN
biopsy is useful for the avoidance of unnecessary dissection
of nonmetastatic nodes16 or determining the final indication
for limited resection such as segmentectomy in those pa-
tients.20 SLN molecular studies could greatly improve the
detection of micrometastases through more focused patho-
logic or molecular evaluation for staging.21 The staining of
serial sections of SLNs by immunochemistry is the most
frequently reported method of identifying micrometastases.
Molecular analysis by reverse transcriptase–polymerase1512 The Journal of Thoracic and Cardiovascular Surchain reaction offers a sensitive tool for the detection of
micrometastasis. However, because the prognostic signifi-
cance of molecular upstaging in lung cancer is not yet
known, adjuvant chemotherapy has not been recommended
in patients with micrometastases in lymph nodes.21 With
increased experience, this technique may be useful in the
management of early-stage lung cancer.
NIR fluorescence imaging for SLN mapping enables
real-time visualization of SLN and lymphatic vessels. It
has clear advantages over conventional methods such as
blue dyes and radioisotopes owing to higher visibility in
thick tissues and no radiation risk of NIR wavelength.7,13
A number of groups used NIR fluorescence imaging
systems in preclinical and clinical studies.6,14,16,17,22
These devices were constructed either for open surgery or
for thoracoscopic surgery.
As shown in Figure 1, we built an intraoperative color and
fluorescence imaging system (ICFIS) for SLN detection in
lung cancer surgery. Color and fluorescence merged images
allowed real-time visualization of SLNs within the context
of color surgical anatomy, enabling image-guided surgery
without switching camera channels. Owing to real-time
contrast control software, the dim fluorescence can be effec-
tively displayed over the color images without switching or
dimming the light in the operating room.6,23 For clinical
translation, the excitation beam being delivered via the
bifurcated optical fiber bundles needs to be replaced bygery c December 2013
FIGURE 4. A, Comparison of ICG and ICG:HSA mapped lymph node NIR fluorescence images in the rat. A 0.1-mL dose of the ICG or ICG:HSA
was injected into the food pad. Each is displayed in NIR fluorescence images (left columns) and fusion images (right columns) using excitation light at
10 mW/cm2. Each is displayed in in vivo SLN images (big square) and ex vivo SLN images (small square). B, SBR of ICG and ICG:HSA for in vivo
SLN mapping. SBR (mean SD) over time in the lymph nodes of rats (n ¼ 5 independent animals for each tracer). ICG, Indocyanine green; HSA, human
serum albumin; NIR, near-infrared; SLN, sentinel lymph node; SBR, signal to background ratio.




Sbright light-emitting diode sources for clinical safety.
Except for this, the ICFIS has features similar to other fluo-
rescence imaging systems that are useful for intraoperative
procedures, and the results of SLN identification rate
described in this study demonstrate the clinical feasibility
of ICFIS in humans.
Recent trends for lung cancer surgery are minimally inva-
sive approaches through video-assisted thoracoscopic
surgery systems. Several NIR fluorescence thoracoscopicThe Journal of Thoracic and Carimaging systems connected with standard thoracoscopes
have been introduced by other groups. However, commer-
cially available thoracoscopes have poor transmission for
the NIR wavelengths, delivering only a low portion of
SBR fluorescence signals. To minimize this problem
when ICFIS is finally coupled with the thoracoscopic sys-
tems, we will use a custom-built real-time contrast control
software that would lower the least power of NIR excitation
light necessary. Currently, we nearly manufactured thediovascular Surgery c Volume 146, Number 6 1513
FIGURE 5. Comparison of ICG and ICG:HSAmapped lymph node NIR fluorescence images in preclinical trial. For each is displayed a color image (first
column), a NIR-fluorescence image (second column), contrast-enhanced and pseudo-colored image (third column), and a fusion image (fourth column) using
excitation light at 5 mW/cm2. Sentinel lymph nodes (arrows) and injected site (white dotted arrows) were visualized well with both tracers. ICG, Indoc-
yanine green; HSA, human serum albumin; NIR, near-infrared.




Sthoracoscopic version of ICFIS, and the clinical feasibility
may be validated in a future study.
Among various NIR fluorescence dyes for SLNmapping,
ICG dyes are currently available dyes approved by the Food
and Drug Administration. Accordingly, a number of pre-
clinical and clinical studies using these dyes have been pub-
lished.14,18 In addition, recent reports note that ICG:HSA
(premixing ICG with HSA) increases the fluorescence
intensity and the hydrodynamic diameter, giving better
SLN retention with an improved detection rate over ICG
alone.18 Our group has conducted a dose-finding study
and demonstrated that the optimal concentration of ICG
and ICG:HSA for NIR-based SLN mapping in animal stud-
ies lies in the range of 5 mg/kg (Figure 3). Even though our
doses of ICG and ICG:HSA are significantly lower than
those of other studies, ICFIS is sensitive enough to display
the necessary signals in real time.14 We also submit that the
dose higher than what we propose does not guarantee
brighter fluorescence signals.
Comparing ICG with or without albumin premixing, our
results imply that there is no significant difference in detect-
ing SLN when the ICG concentrations in both solutions
were identical. In the rat thigh, SBR of ICG and ICG:HSA
were similar and remained constant from 30 to 120 minutes
after injection (Figure 4). This result implies that ICG and
ICG:HSA provided similar retention rates in the SLN.
Although we did not get statistically significant results, in
the porcine lung, ICG provided higher total fluorescence
yield compared with ICG:HSA after 30 minutes
(Figure 5). ICG is likely to flow more rapidly through nar-
row lymphatic channels, owing to its smaller hydrodynamic
diameter than ICG:HSA, and get absorbed by the albumin
abundant in lymph fluid. The longer traveling distance be-
tween the injection site and SLN could cause additional1514 The Journal of Thoracic and Cardiovascular Surabsorption of ICG to albumin in the lymph fluid. Inasmuch
as porcine lung has longer lymphatic channels than rat
thigh, the retention rate of ICG was slightly higher than
ICG:HSA in porcine lung whereas the retention rate of
both fluorophores was the same in rat thigh. Big animal
studies were consistent with the clinical results conducted
for breast cancer, in that ICG provided slightly higher total
fluorescence yield than ICG:HSA at early times.14 From
this study, for surgery for patients with lung cancer, injec-
tion at the primary tumor could cause still more increased
traveling distance, aiding ICG absorption to albumin. As
a result, ICG is likely to provide similar or better retention
rate in SLN than ICG:HSA in lung cancer. These observa-
tions suggest the superiority of ICG as the currently avail-
able optimal fluorescent lymphotrophic tracer over
ICG:HSA in lung cancer surgery, thereby reducing the
cost and complexity of the procedure of premixing ICG
with albumin.14
In conclusion, we developed an ICFIS for lung cancer
surgery and performed a preclinical study of SLN mapping
comparing ICG with or without albumin in the rat thigh and
pig lung. Considering the anatomic structure of the lung, the
ICG without premixing with albumin is considered to be
enough fluorescent tracer inasmuch as it has little or no
influence on the surgical outcome.References
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